| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.877 | 0.004 | 0.877 | Antiadrenergic | 0.61 0.005 DBMET00809 | ||
| 0.876 | 0.004 | 0.876 | Adrenaline antagonist | 0.608 0.005 DBMET00809 | ||
| 0.752 | 0.005 | 0.752 | Cardiotonic | 0.629 0.006 DBMET00809 | ||
| 0.736 | 0.005 | 0.75 | Vasodilator, peripheral | 0.75 0.005 DBMET00809 | DBMET00809 | |
| 0.659 | 0.008 | 0.659 | Spasmolytic | 0.614 0.012 DBMET00809 | ||
| 0.576 | 0.009 | 0.657 | Vasodilator, coronary | 0.657 0.005 DBMET00809 | DBMET00809 | |
| 0.531 | 0.031 | 0.531 | Antiobesity | 0.425 0.057 DBMET00809 | ||
| 0.492 | 0.013 | 0.492 | Vasodilator | 0.434 0.018 DBMET00809 | ||
| 0.463 | 0.005 | 0.494 | Anesthetic local | 0.494 0.004 DBMET00809 | DBMET00809 | |
| 0.457 | 0.004 | 0.457 | Nav1.3 sodium channel blocker | 0.43 0.004 DBMET00809 | ||
| 0.495 | 0.052 | 0.495 | Cyclophilin D inhibitor | 0.49 0.053 DBMET00809 | ||
| 0.425 | 0.002 | 0.425 | Beta adrenoreceptor antagonist | 0.274 0.003 DBMET00809 | ||
| 0.405 | 0.013 | 0.433 | Diuretic | 0.433 0.011 DBMET00809 | DBMET00809 | |
| 0.377 | 0.002 | 0.377 | Calcium-sensing receptor antagonist | 0.104 0.004 DBMET00809 | ||
| 0.371 | 0.009 | 0.371 | Nav1.2 sodium channel blocker | 0.254 0.021 DBMET00809 | ||
| 0.356 | 0.003 | 0.356 | Adrenaline agonist | 0.34 0.003 DBMET00809 | ||
| 0.352 | 0.002 | 0.352 | Beta 1 adrenoreceptor antagonist | 0.222 0.003 DBMET00809 | ||
| 0.394 | 0.051 | 0.666 | Cholesterol antagonist | 0.666 0.011 DBMET00809 | DBMET00809 | |
| 0.384 | 0.053 | 0.509 | Antithrombotic | 0.509 0.028 DBMET00809 | DBMET00809 | |
| 0.361 | 0.033 | 0.391 | Sodium/bile acid cotransporter inhibitor | 0.391 0.02 DBMET00809 | DBMET00809 | |
| 0.375 | 0.051 | 0.667 | Aldehyde oxidase inhibitor | 0.667 0.011 DBMET00809 | DBMET00809 | |
| 0.401 | 0.077 | 0.549 | 5 Hydroxytryptamine release inhibitor | 0.549 0.02 DBMET00809 | DBMET00809 | |
| 0.394 | 0.079 | 0.516 | Histamine release inhibitor | 0.516 0.024 DBMET00809 | DBMET00809 | |
| 0.322 | 0.012 | 0.474 | Insulin sensitizer | 0.474 0.004 DBMET00809 | DBMET00809 | |
| 0.308 | 0.003 | 0.308 | Beta 2 adrenoreceptor antagonist | 0.188 0.004 DBMET00809 | ||
| 0.308 | 0.003 | 0.308 | Beta 3 adrenoreceptor antagonist | 0.255 0.003 DBMET00809 | ||
| 0.328 | 0.024 | 0.359 | P-glycoprotein inhibitor | 0.359 0.02 DBMET00809 | DBMET00809 | |
| 0.306 | 0.004 | 0.311 | Calcium antagonist | 0.311 0.004 DBMET00809 | DBMET00809 | |
| 0.275 | 0.009 | 0.275 | ATPase inhibitor | 0.181 0.056 DBMET00809 | ||
| 0.276 | 0.013 | 0.276 | Calcium channel blocker | 0.239 0.019 DBMET00809 | ||
| 0.279 | 0.018 | 0.279 | Interleukin 6 antagonist | 0.23 0.028 DBMET00809 | ||
| 0.271 | 0.021 | 0.271 | Nitric-oxide synthase stimulant | 0.181 0.125 DBMET00809 | ||
| 0.271 | 0.038 | 0.323 | DNA methyltransferase I inhibitor | 0.323 0.019 DBMET00809 | DBMET00809 | |
| 0.241 | 0.01 | 0.241 | Nav1.6 sodium channel blocker | 0.164 0.04 DBMET00809 | ||
| 0.283 | 0.059 | 0.338 | Hypoglycemic | 0.338 0.04 DBMET00809 | DBMET00809 | |
| 0.274 | 0.05 | 0.274 | Psychostimulant | 0.226 0.067 DBMET00809 | ||
| 0.227 | 0.006 | 0.227 | Adenylate cyclase stimulant | 0.175 0.03 DBMET00809 | ||
| 0.239 | 0.022 | 0.345 | Insulin secretagoues | 0.345 0.009 DBMET00809 | DBMET00809 | |
| 0.318 | 0.104 | 0.365 | Immunosuppressant | 0.365 0.079 DBMET00809 | DBMET00809 | |
| 0.299 | 0.093 | 0.327 | Calcium channel activator | 0.327 0.067 DBMET00809 | DBMET00809 | |
| 0.207 | 0.008 | 0.262 | Sphingosine 1-phosphate receptor 4 antagonist | 0.262 0.004 DBMET00809 | DBMET00809 | |
| 0.276 | 0.078 | 0.417 | 5 Hydroxytryptamine release stimulant | 0.417 0.042 DBMET00809 | DBMET00809 | |
| 0.239 | 0.059 | 0.308 | Peptidyltransferase inhibitor | 0.308 0.022 DBMET00809 | DBMET00809 | |
| 0.239 | 0.066 | 0.239 | Interleukin antagonist | 0.2 0.084 DBMET00809 | ||
| 0.333 | 0.16 | 0.364 | Caspase 9 stimulant | 0.364 0.135 DBMET00809 | DBMET00809 | |
| 0.173 | 0.005 | 0.173 | Sphingosine 1-phosphate receptor 4 agonist | 0.165 0.006 DBMET00809 | ||
| 0.257 | 0.09 | 0.257 | Ca(v)3.3 blocker | |||
| 0.228 | 0.062 | 0.296 | DNA methylase inhibitor | 0.296 0.029 DBMET00809 | DBMET00809 | |
| 0.169 | 0.003 | 0.202 | Beta adrenoreceptor agonist | 0.202 0.003 DBMET00809 | DBMET00809 | |
| 0.168 | 0.007 | 0.168 | Glutamate release inhibitor | 0.116 0.024 DBMET00809 | ||
| 0.182 | 0.022 | 0.182 | Bronchodilator | 0.101 0.063 DBMET00809 | ||
| 0.151 | 0.004 | 0.151 | Sphingosine 1-phosphate receptor 3 agonist | 0.14 0.004 DBMET00809 | ||
| 0.169 | 0.022 | 0.287 | Sphingosine 1-phosphate receptor 2 antagonist | 0.287 0.003 DBMET00809 | DBMET00809 | |
| 0.147 | 0.004 | 0.283 | Sphingosine 1-phosphate receptor agonist | 0.283 0.003 DBMET00809 | DBMET00809 | |
| 0.143 | 0.004 | 0.217 | Sphingosine 1-phosphate receptor 1 agonist | 0.217 0.003 DBMET00809 | DBMET00809 | |
| 0.193 | 0.054 | 0.398 | Succinate dehydrogenase inhibitor | 0.398 0.004 DBMET00809 | DBMET00809 | |
| 0.152 | 0.015 | 0.152 | MAP kinase kinase 1 inhibitor | 0.1 0.057 DBMET00809 | ||
| 0.138 | 0.004 | 0.138 | Calcium channel P-type blocker | 0.087 0.01 DBMET00809 | ||
| 0.162 | 0.028 | 0.162 | Calcium channel (voltage-sensitive) blocker | 0.123 0.053 DBMET00809 | ||
| 0.255 | 0.124 | 0.295 | Transcription factor NF kappa B inhibitor | 0.295 0.097 DBMET00809 | DBMET00809 | |
| 0.181 | 0.051 | 0.181 | Amylase inhibitor | 0.158 0.06 DBMET00809 | ||
| 0.134 | 0.013 | 0.14 | Calcium channel L-type blocker | 0.14 0.012 DBMET00809 | DBMET00809 | |
| 0.147 | 0.026 | 0.163 | Sphingomyelinase inhibitor | 0.163 0.019 DBMET00809 | DBMET00809 | |
| 0.204 | 0.084 | 0.204 | ErbB-1 antagonist | 0.166 0.141 DBMET00809 | ||
| 0.163 | 0.043 | 0.211 | Sphingosine 1-phosphate receptor 5 antagonist | 0.211 0.008 DBMET00809 | DBMET00809 | |
| 0.123 | 0.004 | 0.123 | Beta 2 adrenoreceptor agonist | 0.107 0.004 DBMET00809 | ||
| 0.163 | 0.048 | 0.306 | Alpha-N-acetylglucosaminidase inhibitor | 0.306 0.015 DBMET00809 | DBMET00809 | |
| 0.148 | 0.034 | 0.164 | Nav1.1 sodium channel blocker | 0.164 0.028 DBMET00809 | DBMET00809 | |
| 0.12 | 0.007 | 0.12 | Heat shock protein 90 beta antagonist | |||
| 0.143 | 0.031 | 0.196 | UDP-glucose 4-epimerase inhibitor | 0.196 0.019 DBMET00809 | DBMET00809 | |
| 0.224 | 0.114 | 0.259 | Gastrin inhibitor | 0.259 0.069 DBMET00809 | DBMET00809 | |
| 0.214 | 0.108 | 0.277 | Interleukin agonist | 0.277 0.061 DBMET00809 | DBMET00809 | |
| 0.216 | 0.115 | 0.357 | Transcription factor STAT3 inhibitor | 0.357 0.03 DBMET00809 | DBMET00809 | |
| 0.128 | 0.03 | 0.33 | Electrolyte absorption antagonist | 0.33 0.004 DBMET00809 | DBMET00809 | |
| 0.137 | 0.041 | 0.137 | Mucolytic | 0.126 0.049 DBMET00809 | ||
| 0.134 | 0.04 | 0.134 | CDK3/cyclin E inhibitor | |||
| 0.164 | 0.072 | 0.18 | Arachidonic acid antagonist | 0.18 0.054 DBMET00809 | DBMET00809 | |
| 0.215 | 0.125 | 0.402 | 5 Hydroxytryptamine uptake stimulant | 0.402 0.014 DBMET00809 | DBMET00809 | |
| 0.16 | 0.073 | 0.16 | Peroxidase inhibitor | 0.156 0.075 DBMET00809 | ||
| 0.207 | 0.123 | 0.207 | Tyrosine 3 hydroxylase inhibitor | |||
| 0.085 | 0.003 | 0.152 | Beta 1 adrenoreceptor agonist | 0.152 0.002 DBMET00809 | DBMET00809 | |
| 0.147 | 0.068 | 0.147 | Mannose-6-phosphate isomerase inhibitor | |||
| 0.126 | 0.047 | 0.126 | Expectorant | 0.106 0.062 DBMET00809 | ||
| 0.092 | 0.021 | 0.092 | Adrenaline uptake inhibitor | |||
| 0.115 | 0.045 | 0.115 | Anabolic | 0.107 0.054 DBMET00809 | ||
| 0.179 | 0.111 | 0.293 | Hypolipemic | 0.293 0.051 DBMET00809 | DBMET00809 | |
| 0.158 | 0.091 | 0.432 | Phospholipase C inhibitor | 0.432 0.009 DBMET00809 | DBMET00809 | |
| 0.091 | 0.024 | 0.112 | GABA B receptor agonist | 0.112 0.01 DBMET00809 | DBMET00809 | |
| 0.081 | 0.017 | 0.081 | Gonadotropin-releasing hormone receptor agonist | |||
| 0.104 | 0.04 | 0.146 | NADH dehydrogenase inhibitor | 0.146 0.018 DBMET00809 | DBMET00809 | |
| 0.066 | 0.003 | 0.141 | Beta 3 adrenoreceptor agonist | 0.141 0.003 DBMET00809 | DBMET00809 | |
| 0.122 | 0.059 | 0.122 | Microtubule formation inhibitor | |||
| 0.09 | 0.03 | 0.113 | Sphingosine 1-phosphate receptor antagonist | 0.113 0.015 DBMET00809 | DBMET00809 | |
| 0.1 | 0.04 | 0.1 | ATPase (Vacuolar H+) inhibitor | 0.092 0.053 DBMET00809 | ||
| 0.184 | 0.125 | 0.184 | RNA-directed DNA polymerase inhibitor | |||
| 0.124 | 0.066 | 0.261 | Aldehyde dehydrogenase inhibitor | 0.261 0.016 DBMET00809 | DBMET00809 | |
| 0.12 | 0.063 | 0.12 | Calcium channel N-type blocker | |||
| 0.08 | 0.025 | 0.08 | Dopamine uptake inhibitor | |||
| 0.089 | 0.039 | 0.11 | Keratolytic | 0.11 0.025 DBMET00809 | DBMET00809 | |
| 0.068 | 0.02 | 0.104 | Sphingosine 1-phosphate receptor 1 antagonist | 0.104 0.008 DBMET00809 | DBMET00809 | |
| 0.071 | 0.024 | 0.141 | Sphingosine 1-phosphate receptor 3 antagonist | 0.141 0.004 DBMET00809 | DBMET00809 | |
| 0.122 | 0.076 | 0.222 | Toll-Like receptor 2 antagonist | 0.222 0.015 DBMET00809 | DBMET00809 | |
| 0.114 | 0.071 | 0.175 | Cholesterol synthesis inhibitor | 0.175 0.034 DBMET00809 | DBMET00809 | |
| 0.072 | 0.03 | 0.101 | Prostaglandin F2 alpha antagonist | 0.101 0.011 DBMET00809 | DBMET00809 | |
| 0.104 | 0.065 | 0.168 | AMP-activated protein kinase stimulant | 0.168 0.019 DBMET00809 | DBMET00809 | |
| 0.062 | 0.024 | 0.062 | Nicotinic alpha3beta2 receptor antagonist | |||
| 0.108 | 0.071 | 0.108 | Nav1.5 sodium channel blocker | |||
| 0.089 | 0.055 | 0.266 | NMDA receptor antagonist | 0.266 0.008 DBMET00809 | DBMET00809 | |
| 0.042 | 0.008 | 0.042 | Sodium/glucose cotransporter 2 inhibitor | |||
| 0.078 | 0.044 | 0.153 | Histidine decarboxylase inhibitor | 0.153 0.019 DBMET00809 | DBMET00809 | |
| 0.094 | 0.061 | 0.096 | Potassium channel (Ca-activated) activator | 0.096 0.059 DBMET00809 | DBMET00809 | |
| 0.184 | 0.151 | 0.217 | Neuropeptide Y2 antagonist | 0.217 0.093 DBMET00809 | DBMET00809 | |
| 0.06 | 0.028 | 0.089 | Thromboxane A2 antagonist | 0.089 0.011 DBMET00809 | DBMET00809 | |
| 0.118 | 0.087 | 0.123 | Bone formation stimulant | 0.123 0.083 DBMET00809 | DBMET00809 | |
| 0.119 | 0.09 | 0.122 | Vanilloid 1 agonist | 0.122 0.083 DBMET00809 | DBMET00809 | |
| 0.05 | 0.022 | 0.05 | HIV-1 protease inhibitor | |||
| 0.069 | 0.041 | 0.069 | MDM2 inhibitor | 0.064 0.058 DBMET00809 | ||
| 0.099 | 0.071 | 0.12 | Toll-Like receptor 4 antagonist | 0.12 0.044 DBMET00809 | DBMET00809 | |
| 0.06 | 0.032 | 0.099 | Thromboxane antagonist | 0.099 0.012 DBMET00809 | DBMET00809 | |
| 0.044 | 0.017 | 0.071 | Phosphoglycerate kinase inhibitor | 0.071 0.009 DBMET00809 | DBMET00809 | |
| 0.07 | 0.043 | 0.07 | Phosphodiesterase III inhibitor | |||
| 0.083 | 0.057 | 0.083 | Estrogen-related receptor beta agonist | |||
| 0.04 | 0.013 | 0.04 | Cholesterol ester transfer protein antagonist | 0.033 0.02 DBMET00809 | ||
| 0.132 | 0.107 | 0.153 | Ca2+-transporting ATPase inhibitor | 0.153 0.035 DBMET00809 | DBMET00809 | |
| 0.034 | 0.009 | 0.034 | Sodium/glucose cotransporter inhibitor | |||
| 0.056 | 0.032 | 0.068 | Sphingosine 1-phosphate receptor 5 agonist | 0.068 0.018 DBMET00809 | DBMET00809 | |
| 0.155 | 0.131 | 0.155 | Neurotrophic factor enhancer | |||
| 0.034 | 0.011 | 0.034 | CC chemokine 1 receptor antagonist | |||
| 0.052 | 0.03 | 0.052 | Dopamine transporter inhibitor | |||
| 0.085 | 0.067 | 0.152 | Triose-phosphate isomerase inhibitor | 0.152 0.019 DBMET00809 | DBMET00809 | |
| 0.034 | 0.017 | 0.088 | Lysophosphatidic acid 2 receptor antagonist | 0.088 0.005 DBMET00809 | DBMET00809 | |
| 0.064 | 0.047 | 0.064 | Fibroblast growth factor 2 antagonist | |||
| 0.055 | 0.038 | 0.055 | Cathepsin D inhibitor | 0.052 0.04 DBMET00809 | ||
| 0.039 | 0.023 | 0.039 | Nicotinic receptor beta4 subunit antagonist | |||
| 0.142 | 0.128 | 0.142 | MAP kinase kinase 2 inhibitor | |||
| 0.098 | 0.084 | 0.098 | Interleukin 1b antagonist | |||
| 0.095 | 0.082 | 0.122 | Factor V inhibitor | 0.122 0.037 DBMET00809 | DBMET00809 | |
| 0.128 | 0.115 | 0.157 | Interferon gamma antagonist | 0.157 0.07 DBMET00809 | DBMET00809 | |
| 0.034 | 0.022 | 0.034 | Growth hormone releasing factor agonist | |||
| 0.118 | 0.108 | 0.129 | Farnesoid X receptor antagonist | 0.129 0.084 DBMET00809 | DBMET00809 | |
| 0.04 | 0.03 | 0.047 | Plasmepsin II inhibitor | 0.047 0.02 DBMET00809 | DBMET00809 | |
| 0.066 | 0.057 | 0.066 | Secretase beta inhibitor | |||
| 0.055 | 0.046 | 0.055 | Calcium channel T-type blocker | |||
| 0.086 | 0.079 | 0.086 | Protease inhibitor | |||
| 0.054 | 0.048 | 0.057 | Pregnane X receptor antagonist | 0.057 0.039 DBMET00809 | DBMET00809 | |
| 0.1 | 0.094 | 0.1 | MAP kinase kinase inhibitor | |||
| 0.077 | 0.071 | 0.196 | Ornithine decarboxylase inhibitor | 0.196 0.005 DBMET00809 | DBMET00809 | |
| 0.026 | 0.021 | 0.026 | Myristoyl transferase inhibitor | |||
| 0.122 | 0.118 | 0.149 | Neuropeptide Y1 antagonist | 0.149 0.066 DBMET00809 | DBMET00809 | |
| 0.03 | 0.027 | 0.041 | Peroxisome proliferator-activated receptor delta agonist | 0.041 0.016 DBMET00809 | DBMET00809 | |
| 0.077 | 0.074 | 0.077 | Alpha adrenoreceptor antagonist | |||
| 0.081 | 0.079 | 0.119 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.119 0.04 DBMET00809 | DBMET00809 | |
| 0.066 | 0.064 | 0.094 | Peroxisome proliferator-activated receptor gamma antagonist | 0.094 0.019 DBMET00809 | DBMET00809 | |
| 0.074 | 0.072 | 0.074 | Androgen antagonist | |||
| 0.152 | 0.153 | 0.364 | Immunostimulant | 0.364 0.06 DBMET00809 | DBMET00809 | |
| 0.057 | 0.062 | 0.068 | Phenylalanine 4-hydroxylase inhibitor | 0.068 0.048 DBMET00809 | DBMET00809 | |
| 0.024 | 0.029 | 0.03 | Plasmepsin I inhibitor | 0.03 0.021 DBMET00809 | DBMET00809 | |
| 0.063 | 0.069 | 0.106 | Topoisomerase II alpha inhibitor | 0.106 0.036 DBMET00809 | DBMET00809 | |
| 0.067 | 0.073 | 0.082 | Vanilloid 4 agonist | 0.082 0.038 DBMET00809 | DBMET00809 | |
| 0.028 | 0.036 | 0.036 | Peroxisome proliferator-activated receptor delta antagonist | 0.036 0.019 DBMET00809 | DBMET00809 | |
| 0.053 | 0.062 | 0.058 | Nitric oxide donor | 0.058 0.052 DBMET00809 | DBMET00809 | |
| 0.075 | 0.084 | 0.09 | Transcription factor NF kappa B stimulant | 0.09 0.051 DBMET00809 | DBMET00809 | |
| 0.005 | 0.014 | 0.009 | Mannitol 2-dehydrogenase inhibitor | 0.009 0.005 DBMET00809 | DBMET00809 | |
| 0.051 | 0.061 | 0.056 | Sphingosine kinase inhibitor | 0.056 0.047 DBMET00809 | DBMET00809 | |
| 0.174 | 0.185 | 0.184 | Thyroid hormone antagonist | 0.184 0.175 DBMET00809 | DBMET00809 | |
| 0.036 | 0.047 | 0.108 | Peroxisome proliferator-activated receptor alpha agonist | 0.108 0.011 DBMET00809 | DBMET00809 | |
| 0.035 | 0.049 | 0.062 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.062 0.006 DBMET00809 | DBMET00809 | |
| 0.018 | 0.032 | 0.02 | Vitamin D receptor antagonist | 0.02 0.019 DBMET00809 | DBMET00809 | |
| 0.034 | 0.048 | 0.039 | Glucagon-like peptide 1 receptor antagonist | 0.039 0.029 DBMET00809 | DBMET00809 | |
| 0.058 | 0.074 | 0.063 | Glutamate (mGluR6) antagonist | 0.063 0.058 DBMET00809 | DBMET00809 | |
| 0.12 | 0.135 | 0.125 | Melanin inhibitor | 0.125 0.124 DBMET00809 | DBMET00809 | |
| 0.058 | 0.073 | 0.094 | Aminopeptidase I inhibitor | 0.094 0.031 DBMET00809 | DBMET00809 | |
| 0.074 | 0.092 | 0.147 | Alcohol dehydrogenase inhibitor | 0.147 0.021 DBMET00809 | DBMET00809 | |
| 0.016 | 0.035 | 0.025 | Prostaglandin F2 alpha agonist | 0.025 0.012 DBMET00809 | DBMET00809 | |
| 0.023 | 0.043 | 0.029 | ATP citrate lysase inhibitor | 0.029 0.026 DBMET00809 | DBMET00809 | |
| 0.018 | 0.038 | 0.03 | Lysophosphatidic acid receptor 1 agonist | 0.03 0.011 DBMET00809 | DBMET00809 | |
| 0.169 | 0.189 | 0.284 | Transcription factor STAT inhibitor | 0.284 0.065 DBMET00809 | DBMET00809 | |
| 0.069 | 0.09 | 0.101 | Histamine H2 receptor antagonist | 0.101 0.034 DBMET00809 | DBMET00809 | |
| 0.047 | 0.069 | 0.066 | Adenine nucleotide translocase inhibitor | 0.066 0.019 DBMET00809 | DBMET00809 | |
| 0.044 | 0.067 | 0.062 | Epithelial sodium channel blocker | 0.062 0.025 DBMET00809 | DBMET00809 | |
| 0.005 | 0.028 | 0.011 | Thromboxane agonist | 0.011 0.007 DBMET00809 | DBMET00809 | |
| 0.16 | 0.184 | 0.239 | DNA synthesis inhibitor | 0.239 0.074 DBMET00809 | DBMET00809 | |
| 0.042 | 0.065 | 0.063 | Alpha-mannosidase inhibitor | 0.063 0.024 DBMET00809 | DBMET00809 | |
| 0.181 | 0.207 | 0.241 | Calpain 2 inhibitor | 0.241 0.156 DBMET00809 | DBMET00809 | |
| 0.011 | 0.038 | 0.056 | Prostaglandin EP2 agonist | 0.056 0.005 DBMET00809 | DBMET00809 | |
| 0.073 | 0.1 | 0.105 | Creatine kinase inhibitor | 0.105 0.054 DBMET00809 | DBMET00809 | |
| 0.186 | 0.215 | 0.298 | Interleukin 2 agonist | 0.298 0.075 DBMET00809 | DBMET00809 | |
| 0.142 | 0.172 | 0.157 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.157 0.132 DBMET00809 | DBMET00809 | |
| 0.04 | 0.072 | 0.094 | Neuraminidase inhibitor | 0.094 0.018 DBMET00809 | DBMET00809 | |
| 0.024 | 0.059 | 0.031 | Glutamate (mGluR3) agonist | 0.031 0.024 DBMET00809 | DBMET00809 | |
| 0.015 | 0.05 | 0.041 | Prostaglandin EP4 antagonist | 0.041 0.01 DBMET00809 | DBMET00809 | |
| 0.034 | 0.071 | 0.08 | Lysophosphatidic acid 3 receptor antagonist | 0.08 0.009 DBMET00809 | DBMET00809 | |
| 0.051 | 0.088 | 0.096 | Glutamate decarboxylase inhibitor | 0.096 0.032 DBMET00809 | DBMET00809 | |
| 0.063 | 0.103 | 0.115 | Glutathione S-transferase inhibitor | 0.115 0.025 DBMET00809 | DBMET00809 | |
| 0.05 | 0.09 | 0.066 | Potassium channel large-conductance Ca-activated activator | 0.066 0.049 DBMET00809 | DBMET00809 | |
| 0.012 | 0.052 | 0.025 | Kynurenine 3 monooxygenase inhibitor | 0.025 0.02 DBMET00809 | DBMET00809 | |
| 0.028 | 0.071 | 0.058 | Mannosidase inhibitor | 0.058 0.018 DBMET00809 | DBMET00809 | |
| 0.037 | 0.08 | 0.069 | Squalene epoxidase inhibitor | 0.069 0.014 DBMET00809 | DBMET00809 | |
| 0.033 | 0.077 | 0.136 | Acyl-CoA dehydrogenase inhibitor | 0.136 0.01 DBMET00809 | DBMET00809 | |
| 0.005 | 0.05 | 0.025 | Peroxisome proliferator-activated receptor alpha antagonist | 0.025 0.013 DBMET00809 | DBMET00809 | |
| 0.064 | 0.11 | 0.096 | Urease inhibitor | 0.096 0.072 DBMET00809 | DBMET00809 | |
| 0.033 | 0.079 | 0.102 | Prostaglandin EP2 antagonist | 0.102 0.018 DBMET00809 | DBMET00809 | |
| 0.009 | 0.055 | 0.04 | Prostaglandin E2 agonist | 0.04 0.007 DBMET00809 | DBMET00809 | |
| 0.015 | 0.062 | 0.06 | Prostaglandin agonist | 0.06 0.008 DBMET00809 | DBMET00809 | |
| 0.128 | 0.176 | 0.225 | Antiamyloidogenic | 0.225 0.084 DBMET00809 | DBMET00809 | |
| 0.004 | 0.052 | 0.031 | Prostaglandin EP4 agonist | 0.031 0.007 DBMET00809 | DBMET00809 | |
| 0.084 | 0.132 | 0.177 | Cyclooxygenase 3 inhibitor | 0.177 0.029 DBMET00809 | DBMET00809 | |
| 0.046 | 0.094 | 0.068 | Leukotriene C antagonist | 0.068 0.016 DBMET00809 | DBMET00809 | |
| 0.044 | 0.094 | 0.172 | Catalase inhibitor | 0.172 0.021 DBMET00809 | DBMET00809 | |
| 0.051 | 0.103 | 0.098 | Glutamate dehydrogenase inhibitor | 0.098 0.032 DBMET00809 | DBMET00809 | |
| 0.059 | 0.112 | 0.161 | Aminopeptidase B inhibitor | 0.161 0.033 DBMET00809 | DBMET00809 | |
| 0.012 | 0.066 | 0.017 | Methylmalonyl-CoA mutase inhibitor | 0.017 0.015 DBMET00809 | DBMET00809 | |
| 0.048 | 0.102 | 0.065 | Epoxide hydrolase inhibitor | 0.065 0.062 DBMET00809 | DBMET00809 | |
| 0.078 | 0.132 | 0.118 | Folate antagonist | 0.118 0.041 DBMET00809 | DBMET00809 | |
| 0.034 | 0.089 | 0.072 | Selectin antagonist | 0.072 0.041 DBMET00809 | DBMET00809 | |
| 0.023 | 0.078 | 0.054 | Phosphorylase inhibitor | 0.054 0.028 DBMET00809 | DBMET00809 | |
| 0.11 | 0.165 | 0.209 | Anesthetic general | 0.209 0.069 DBMET00809 | DBMET00809 | |
| 0.038 | 0.095 | 0.085 | Peroxisome proliferator-activated receptor gamma agonist | 0.085 0.037 DBMET00809 | DBMET00809 | |
| 0.045 | 0.103 | 0.09 | Neuraminidase (influenza) inhibitor | 0.09 0.02 DBMET00809 | DBMET00809 | |
| 0.036 | 0.098 | 0.093 | Phosphofructokinase-1 inhibitor | 0.093 0.035 DBMET00809 | DBMET00809 | |
| 0.032 | 0.095 | 0.073 | Aconitate hydratase inhibitor | 0.073 0.017 DBMET00809 | DBMET00809 | |
| 0.029 | 0.094 | 0.044 | Leukotriene C4 antagonist | 0.044 0.016 DBMET00809 | DBMET00809 | |
| 0.009 | 0.075 | 0.03 | Squalene synthetase inhibitor | 0.03 0.024 DBMET00809 | DBMET00809 | |
| 0.067 | 0.136 | 0.133 | Adenylate cyclase inhibitor | 0.133 0.057 DBMET00809 | DBMET00809 | |
| 0.073 | 0.143 | 0.166 | Adenylate kinase inhibitor | 0.166 0.021 DBMET00809 | DBMET00809 | |
| 0.014 | 0.087 | 0.027 | Calcium-sensing receptor agonist | 0.027 0.018 DBMET00809 | DBMET00809 | |
| 0.059 | 0.135 | 0.115 | Gastric antisecretory | 0.115 0.047 DBMET00809 | DBMET00809 | |
| 0.124 | 0.203 | 0.16 | Antioxidant | 0.16 0.154 DBMET00809 | DBMET00809 | |
| 0.012 | 0.093 | 0.03 | Prostaglandin D2 agonist | 0.03 0.022 DBMET00809 | DBMET00809 | |
| 0.135 | 0.215 | 0.386 | Superoxide dismutase inhibitor | 0.386 0.029 DBMET00809 | DBMET00809 | |
| 0.047 | 0.127 | 0.149 | GABA aminotransferase inhibitor | 0.149 0.008 DBMET00809 | DBMET00809 | |
| 0.056 | 0.143 | 0.092 | Aminoacyl-tRNA synthetase inhibitor | 0.092 0.055 DBMET00809 | DBMET00809 | |
| 0.034 | 0.12 | 0.061 | Thromboxane synthase inhibitor | 0.061 0.026 DBMET00809 | DBMET00809 | |
| 0.022 | 0.11 | 0.055 | Prostaglandin E2 antagonist | 0.055 0.031 DBMET00809 | DBMET00809 | |
| 0.02 | 0.107 | 0.108 | Ornithine carbamoyltransferase inhibitor | 0.108 0.015 DBMET00809 | DBMET00809 | |
| 0.013 | 0.102 | 0.024 | Vanilloid 2 agonist | 0.024 0.022 DBMET00809 | DBMET00809 | |
| 0.032 | 0.123 | 0.093 | Leukotriene antagonist | 0.093 0.025 DBMET00809 | DBMET00809 | |
| 0.01 | 0.104 | 0.025 | Lysophosphatidic acid 1 receptor antagonist | 0.025 0.009 DBMET00809 | DBMET00809 | |
| 0.061 | 0.16 | 0.163 | DNA polymerase I inhibitor | 0.163 0.042 DBMET00809 | DBMET00809 | |
| 0.05 | 0.152 | 0.129 | Mediator release inhibitor | 0.129 0.04 DBMET00809 | DBMET00809 | |
| 0.074 | 0.177 | 0.143 | Cathepsin H inhibitor | 0.143 0.052 DBMET00809 | DBMET00809 | |
| 0.119 | 0.222 | 0.21 | Cyclic AMP phosphodiesterase inhibitor | 0.21 0.087 DBMET00809 | DBMET00809 | |
| 0.024 | 0.129 | 0.07 | Alcohol oxidase inhibitor | 0.07 0.029 DBMET00809 | DBMET00809 | |
| 0.075 | 0.18 | 0.143 | Interleukin 4 antagonist | 0.143 0.057 DBMET00809 | DBMET00809 | |
| 0.071 | 0.177 | 0.102 | Electron transport complex I inhibitor | 0.102 0.079 DBMET00809 | DBMET00809 | |
| 0.029 | 0.138 | 0.052 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.052 0.05 DBMET00809 | DBMET00809 | |
| 0.062 | 0.173 | 0.142 | Carbonic anhydrase XV inhibitor | 0.142 0.034 DBMET00809 | DBMET00809 | |
| 0.015 | 0.126 | 0.038 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | 0.038 0.018 DBMET00809 | DBMET00809 | |
| 0.01 | 0.122 | 0.023 | Neuraminidase (Influenza B) inhibitor | 0.023 0.011 DBMET00809 | DBMET00809 | |
| 0.012 | 0.124 | 0.041 | Farnesoid X receptor agonist | 0.041 0.022 DBMET00809 | DBMET00809 | |
| 0.023 | 0.139 | 0.04 | Calcium-independent phospholipase A2 inhibitor | 0.04 0.011 DBMET00809 | DBMET00809 | |
| 0.152 | 0.27 | 0.221 | Caspase 3 stimulant | 0.221 0.142 DBMET00809 | DBMET00809 | |
| 0.064 | 0.188 | 0.113 | Lipid peroxidase inhibitor | 0.113 0.101 DBMET00809 | DBMET00809 | |
| 0.054 | 0.179 | 0.091 | Bile acid receptor antagonist | 0.091 0.07 DBMET00809 | DBMET00809 | |
| 0.154 | 0.281 | 0.223 | GABA C receptor rho-3 antagonist | 0.223 0.181 DBMET00809 | DBMET00809 | |
| 0.017 | 0.146 | 0.056 | Adenosine deaminase inhibitor | 0.056 0.024 DBMET00809 | DBMET00809 | |
| 0.015 | 0.146 | 0.034 | Glutamate (mGluR3) antagonist | 0.034 0.03 DBMET00809 | DBMET00809 | |
| 0.025 | 0.159 | 0.055 | Leukotriene B4 antagonist | 0.055 0.035 DBMET00809 | DBMET00809 | |
| 0.027 | 0.163 | 0.063 | Leukotriene synthesis inhibitor | 0.063 0.051 DBMET00809 | DBMET00809 | |
| 0.075 | 0.218 | 0.289 | Phospholipase A2 inhibitor | 0.289 0.015 DBMET00809 | DBMET00809 | |
| 0.019 | 0.163 | 0.056 | Neuraminidase (Influenza A) inhibitor | 0.056 0.017 DBMET00809 | DBMET00809 | |
| 0.03 | 0.179 | 0.071 | NMDA receptor agonist | 0.071 0.035 DBMET00809 | DBMET00809 | |
| 0.05 | 0.213 | 0.117 | GABA C receptor antagonist | 0.117 0.056 DBMET00809 | DBMET00809 | |
| 0.087 | 0.25 | 0.187 | Platelet antagonist | 0.187 0.112 DBMET00809 | DBMET00809 | |
| 0.078 | 0.242 | 0.145 | Dual specificity phosphatase inhibitor | 0.145 0.1 DBMET00809 | DBMET00809 | |
| 0.048 | 0.224 | 0.113 | GABA C receptor rho-1 antagonist | 0.113 0.046 DBMET00809 | DBMET00809 | |
| 0.059 | 0.237 | 0.126 | Antibacterial (Helicobacter pylori) | 0.126 0.073 DBMET00809 | DBMET00809 | |
| 0.077 | 0.255 | 0.137 | Hepatoprotectant | 0.137 0.125 DBMET00809 | DBMET00809 | |
| 0.054 | 0.243 | 0.08 | Hematopoietic | 0.08 0.074 DBMET00809 | DBMET00809 | |
| 0.062 | 0.257 | 0.151 | Dual specificity phosphatase 3 inhibitor | 0.151 0.096 DBMET00809 | DBMET00809 | |
| 0.092 | 0.288 | 0.127 | MAP kinase kinase 4 inhibitor | 0.127 0.123 DBMET00809 | DBMET00809 | |
| 0.048 | 0.244 | 0.084 | Interleukin 5 antagonist | 0.084 0.065 DBMET00809 | DBMET00809 | |
| 0.023 | 0.221 | 0.049 | Heparanase inhibitor | 0.049 0.047 DBMET00809 | DBMET00809 | |
| 0.065 | 0.277 | 0.131 | Thiol protease inhibitor | 0.131 0.094 DBMET00809 | DBMET00809 | |
| 0.007 | 0.225 | 0.019 | Retinoic acid beta receptor agonist | 0.019 0.015 DBMET00809 | DBMET00809 | |
| 0.089 | 0.309 | 0.164 | DNA damaging | 0.164 0.153 DBMET00809 | DBMET00809 | |
| 0.014 | 0.235 | 0.067 | Argininosuccinate synthase inhibitor | 0.067 0.032 DBMET00809 | DBMET00809 | |
| 0.117 | 0.338 | 0.221 | Insulysin inhibitor | 0.221 0.128 DBMET00809 | DBMET00809 | |
| 0.075 | 0.297 | 0.129 | Antipruritic | 0.129 0.125 DBMET00809 | DBMET00809 | |
| 0.013 | 0.243 | 0.04 | Retinoic acid alpha receptor agonist | 0.04 0.026 DBMET00809 | DBMET00809 | |
| 0.029 | 0.259 | 0.074 | Interferon agonist | 0.074 0.063 DBMET00809 | DBMET00809 | |
| 0.118 | 0.361 | 0.198 | Apoptosis antagonist | 0.198 0.182 DBMET00809 | DBMET00809 | |
| 0.035 | 0.286 | 0.109 | Chelator | 0.109 0.065 DBMET00809 | DBMET00809 | |
| 0.041 | 0.345 | 0.151 | Angiogenesis stimulant | 0.151 0.122 DBMET00809 | DBMET00809 | |
| 0.067 | 0.44 | 0.149 | Lipocortins synthesis antagonist | 0.149 0.107 DBMET00809 | DBMET00809 | |
| 0.024 | 0.41 | 0.134 | Protein-tyrosine phosphatase inhibitor | 0.134 0.096 DBMET00809 | DBMET00809 | |
| 0.025 | 0.421 | 0.119 | Thrombolytic | 0.119 0.112 DBMET00809 | DBMET00809 | |
| 0.073 | 0.47 | 0.274 | Antibacterial | 0.274 0.156 DBMET00809 | DBMET00809 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |